Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firategrast in Relapsing-Remitting Multiple Sclerosis
NCT00395317Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of firategrast in relapsing-remitting multiple sclerosis (RRMS) (5 arms), sponsored by GSK. Primary endpoint: Cumulative number of new gadolinium-enhancing lesions on monthly MRI scans at 24 weeks. Started Dec 2006; status: completed.
02
Drugs
firategrast
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT00395317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395317.